A few days ago, Kangwei Century's IPO was registered with the China Securities Regulatory Commission and will be listed on the Shanghai Stock Exchange Science and Technology Innovation Board. The " China Medical City Sector" in the capital market will add new members.
has gone from "drawing a blueprint on a blank sheet of paper" to settling in more than 1,200 pharmaceutical companies around the world. In the past 10 years, China Medical City has continuously refreshed the biopharmaceutical industry's height, and has made every effort to sprint to "China's No. 1, World Famous" pharmaceutical city Target.
China Medical City Xinzi
This decade is a decade in which the advantages of industrial cluster have been demonstrated. As the country's first national high-tech zone for pharmaceuticals, China Medical City focuses on building a biopharmaceutical characteristic industry cluster, implementing precise policies, strengthening chains, antibody drugs, vaccines, diagnostic reagents and high-end medical devices, new chemical preparations, special Leading industries such as medical formula food have frequent bright spots and prominent advantages.
Zhonghui Yuantong independently developed the national first-class new drug quadrivalent influenza virus subunit vaccine, filling the international gap; Nestlé Health obtained the first domestic registration certificate for special medical full-nutrition formula food; Maibotec injection infliximab became the first domestic The first infliximab biosimilar drug to be approved for marketing; Huatai Chenguang compound pain reliever was officially approved, becoming the first domestic generic drug of this variety... One by one, the "first" and "only" at home and abroad, building up A highland for the biopharmaceutical industry. The
data is the best "barometer". By the end of 2021, the park has 80 Class I new drugs under development and application, 52 clinical approvals have been obtained, 4 Class I new drug products have been approved for production, and 8 Class I new drug production approvals have been obtained; 43 drug manufacturers have obtained production approvals. License, 73 production lines of 24 enterprises have passed GMP certification, (inspection), and have obtained 196 drug clinical trial approvals and 168 drug registration approvals; 170 medical device manufacturers have been put into production, and the existing medical device registration certificates and 2,795 filing certificates, including 1,013 second- and third-class registration certificates; 20 food production licenses (including 7 special food), 184 health food registration certificates and filing certificates, and 3 special medical formula food registration certificates Zhang; obtained cosmetics production license 8, and 392 filing certificates.
This year, there are many good news. Not long ago, Ruike Biotech's second-generation new crown vaccine obtained the " drug production license ", becoming the fifth human vaccine company in the park to obtain a production license, and the fourth in the province. A new crown vaccine production license. At present, 5 domestic vaccine companies have obtained production licenses in the park, accounting for 5/9 of the province and 1/9 of the country. Whether it is the number of enterprises that have obtained production licenses or the number of products, the agglomeration degree is the highest in the park in the country.
This decade is a decade of accelerated uplift of the capital medicine city sector.
On March 31 this year, Ruike Bio was listed in Hong Kong, becoming the first stock of HPV on the Hong Kong Stock Exchange. So far, there are 8 local listed companies in China Medical City. Whether
is a listed company has become an important criterion for measuring the success of an enterprise. Behind the "blooming and fruiting" of many pharmaceutical companies is the strong support of China Medical City's diversified financial services.
Jindike Bio, which landed on the Science and Technology Innovation Board in August last year, has gone through many difficult times during its more than ten years of business. The support of the medical high-tech zone's own funds and the timely injection of social capital have finally allowed the company to tide over the crisis. , ushered in the listing. Jindike is the epitome of many enterprises in China Medical City. Many entrepreneurial teams came to China Medical City with "one poor and two white". Under the "oxygen supply" of various financial service systems, they gradually developed and expanded, and finally went to the whole country and the world. In the past ten years, 14 state-owned funds have been established in the pharmaceutical high-tech zone, including 1 parent fund, angel investment fund 1, venture capital fund 2, and 10 private equity investment funds. These funds meet the financial needs of pharmaceutical companies at different stages of development, allowing companies to go from "fear of listing" to "striving for listing".
In February 2019, the Pharmaceutical High-tech Zone issued the "Implementation Opinions on Promoting the Listing (Listing) of Enterprises", and used real money to encourage enterprises to go public, and the highest level of financial incentives at the provincial and municipal levels was 11.2 million yuan. Under the policy dividend, in that year, China Medical City realized 3 companies listed. In November 2021, the Pharmaceutical High-tech Zone ( Gaogang District ) once again issued the "Implementation Opinions on Promoting the Listing (Listing) of Enterprises" to encourage enterprises to restructure into joint stock companies.Companies, companies listed at home and abroad (listing), and the sustainable development of listed companies will be given a package of support. Among them, companies that successfully go public (listed) will receive 6.7 million yuan in rewards and subsidies at the highest district level. "Incentive principle, enterprises can still enjoy other incentive policies at the municipal level and above. At the same time as the
policy was introduced, the China Medical City Listed Enterprise Alliance was established simultaneously, and successively cultivated a reserve army of listed companies. It is expected that by 2025, the number of local listed companies in China Medical City will exceed 20. The listing of the
company brought the industry to take off. In 2021, China Medical City will realize general public budget tax revenue of 1.218 billion yuan, a year-on-year increase of 42.9%; industrial storage tax revenue of 1.054 billion yuan; 10 enterprises with a net tax increase of more than 10 million yuan, and 24 enterprises with tax payments exceeding 10 million yuan ; Realized 15 billion yuan for industrial invoices, 29.3 billion yuan for pharmaceutical industry invoices, and 36.86 billion yuan for full-caliber invoices, a year-on-year increase of 32.7%, 26.1%, and 20.5% respectively; 14 new industrial enterprises were added, and the total industrial output value was 139.26 yuan. 100 million yuan, a year-on-year increase of 25.7%. At present, there are 72 high-tech enterprises in the park and 67 industrial enterprises on the scale. This decade of
has been a decade of rapid gathering of high-end talents.
On May 29, 2009, Taizhou Pharmaceutical High-tech Zone was officially listed, and this day was also defined as "China Medical City Talent Day". In the past ten years, in order to fully serve the enterprise, recruit talents and accelerate the gathering of talents, Taizhou City has "strengthen the city's efforts to build China Medical City", and has allocated 100 million yuan of special funds every year to support the development of talents in China Medical City, forming a A talent support system with three gradients including "113 Special Plan for Pharmaceutical Industry Talents", "Provincial Innovation and Entrepreneurship Plan" and national high-end talents has been established.
On May 29 this year, the 2022 China Medical City International Talent Cloud Conference was held in the Medical High-tech Zone (Gaogang District). At the meeting, 3 overseas talent liaison stations and more than 20 talent projects were officially signed and settled, covering biopharmaceuticals, In the fields of medical devices, health management, stem cell therapy, etc., in the form of exclusive festivals, we pay tribute to and applaud talents with the highest courtesy and sincerity, and fully play the "strongest voice" of respecting and loving talents.
Up to now, China Medical City has introduced more than 4,300 high-level biomedical talents at home and abroad, has flexibly introduced 10 academicians of and Chinese Academy of Sciences, 60 national-level high-end experts, and locally applied for "mass entrepreneurship and innovation talents" in Jiangsu Province134 There are 1,369 high-level talents of various types and "113", and the high-end talents are among the best in similar parks in the country. This decade of
has been a decade of continuous optimization of the business environment.
innovation is the endogenous driving force for the development of the park. In order to gather high-quality resources and promote the innovation and development of enterprises, China Medical City, relying on the advantages of "co-construction by ministries and provinces", continues to deepen the cooperation between large institutes and institutes, and cooperates with the China Biotechnology Development Center of the Ministry of Science and Technology and the International Genetic Engineering and Biotechnology Center . Build the world's first regional research center of ICGEB; jointly build a pharmaceutical and health industry innovation center with Peking University School of Medicine ; platform carriers such as the Dalian Institute of Biomedical Innovation Research Institute of the Chinese Academy of Sciences and the Institute of Health Sciences of Fudan University are accelerating the construction.
In order to help enterprises reduce costs and avoid risks, China Medical City has built a public service platform covering the entire life cycle of pharmaceutical development in accordance with the concept of "enterprise construction, market-oriented operation, professional management, and internationalization goals". 21 public technical service platforms, including the Vaccine Engineering Center and the Drug Safety Evaluation Center, provide professional services such as drug screening, pharmaceutical research, formulation research, pilot scale-up, safety evaluation, and CMO commissioned production. Among them, the Vaccine Engineering Center has the largest scale in China. , The only vaccine achievement transformation base in the province, with a total of 19 hatched enterprises, participating in 6 new crown vaccine clinical trials and clinical sample testing covering 5 technical routes nationwide, realizing the true sense of innovation and entrepreneurship talents "Bring in the bag".
Over the past ten years, China Medical City has always adhered to the "nanny-style" service and "professional people do professional things", and set up services in a process-based manner around the registration and settlement of pharmaceutical companies, technology incubation, new drug declaration, financial support, and talent hunting. Department; set up more than 100 high-level talent service teams from Peking University, Tsinghua University, and Union Medical College, and regularly go to relevant national ministries and commissions to study on a temporary basis, including more than 30 professional application teams.The company provides whole-process and all-round caring services; it has established a branch directly under the China Medical City of the Jiangsu Provincial Drug Administration, and has built a branch of the Jiangsu Provincial Institute of Instrument Testing, which has 118 testing capabilities such as biochemistry, immunity, and chemiluminescence. Enterprise escort.
Enterprise Story
"Nanny-style" service helps enterprises take off The horizontal GMP pilot plant and modern R&D center have become "the potential unicorn enterprise in the high-tech zone of Jiangsu Province". Founder Jiang Zhijun said that all of this is inseparable from the high-quality business environment of China Medical City. At the end of 2009, Jiang Zhijun returned to China with his entrepreneurial dream, and visited Guangzhou, Shanghai, Suzhou, Wuxi, Nanjing, Yixing, Taizhou, and many cities. After comprehensive consideration of all aspects, Taizhou was chosen resolutely. He said that compared with other cities, China Medical City focuses on the field of medicine, with a professional team, clear direction, clear thinking, and more importantly, tailor-made for companies in the early stage of business, including major project awards, standard factory discounts, tax contributions A package of support policies including incentives, talent incentives, innovation incentives, etc., are deeply attractive to entrepreneurs. As an enterprise focusing on the R&D and industrialization of new respiratory and psychiatric drugs,
has a large initial R&D investment and a long cycle, and financing is critical. Jiang Zhijun still remembers that in 2017, Changtai Pharmaceutical successfully obtained 50 million yuan in financing. Just as everyone was working hard to make a big show, they were told by the employer that the funds could not be in place on time and would be postponed for a month, which undoubtedly affected the operation of the company. to risk. "Once the capital chain breaks, the survival of the company is at stake." Jiang Zhijun was so anxious that he couldn't sleep all night. After learning the news, the park immediately communicated with the capital, and used government relations to help the company coordinate bank resources. In less than two weeks, the park successfully obtained a loan of 50 million yuan, which solved the urgent need of the company.
In the process of enterprise GMP certification, the park provides the whole "nanny-style" service. "We are not very familiar with the materials and processes required for the new version of GMP certification. The park specially arranges a special person to provide one-on-one caring services to help us connect in advance, standardize the construction of the plant according to the requirements, prepare relevant materials, and complete various certification procedures. We do not need us at all. Worry about it." Jiang Zhijun said that during the process of new drug registration and application, the staff of the park also accompanied the whole process. At any stage, which procedures should be handled, they would directly help to complete the procedures, and they also traveled to the province for repeated docking, which made the company feel very at ease.
